Premium
Hypermethylation of CSF3R is a novel cisplatin resistance marker and predictor of response to postoperative chemotherapy in hepatoblastoma
Author(s) -
Fujiyoshi Sunao,
Honda Shohei,
Minato Masashi,
Ara Momoko,
Suzuki Hiromu,
Hiyama Eiso,
Taketomi Akinobu
Publication year - 2020
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.13479
Subject(s) - hepatoblastoma , cisplatin , chemotherapy , oncology , medicine , predictive marker , cancer research , cancer
Aim Most hepatoblastoma patients undergo pre/postoperative cisplatin treatment. Approximately 20% patients are cisplatin resistant, and show poor prognosis and high recurrence rates. However, some cisplatin‐sensitive patients show early recurrence. We consider that a small population of cisplatin‐resistant cells may remain after preoperative chemotherapy. Previous studies showed a correlation between DNA hypermethylation and hepatoblastoma progression. Here, we examined whether DNA hypermethylation was related to cisplatin resistance and could be a potential indicator for cisplatin as postoperative chemotherapy. Methods We extracted DNA from 43 resected hepatoblastoma tumors. Methylation array analyses were performed in 11 samples, including six cisplatin‐sensitive and five cisplatin‐resistant samples. We also performed cDNA microarray analysis in parental and cisplatin‐resistant HuH6 cells. Through comparison of the datasets, we selected the strongest correlated cisplatin‐resistant candidate gene. Using bisulfite pyrosequencing, the candidate gene methylation level was assessed in 38 cisplatin‐sensitive patients after checking its usefulness as a substitute modality of methylation array. Correlations between the methylation status and clinical data were analyzed. Results CSF3R was the strongest correlated variable. Bisulfite pyrosequencing analysis also confirmed CSF3R was significantly hypermethylated in cisplatin‐resistant patients. Among the 38 cisplatin‐sensitive patients, recurrence curves showed that the CSF3R high methylation patients had significantly higher recurrence than CSF3R low methylation patients. The recurrence curve of methylation high patients was similar to that of cisplatin‐resistant patients. Conclusions Our findings suggested that CSF3R hypermethylation was related to cisplatin resistance in HB patients and could be a predictor of postoperative chemotherapy, and indicate that CSF3R high methylation patients should be treated with non‐CDDP regimens.